China Medical System Holdings Limited (HKG:0867)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 34.69B +74.8% |
| Revenue (ttm) | 9.14B +9.9% |
| Net Income | 1.66B -8.1% |
| EPS | 0.68 -7.8% |
| Shares Out | 2.42B |
| PE Ratio | 20.93 |
| Forward PE | 15.06 |
| Dividend | 0.33 (2.32%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 6,923,223 |
| Average Volume | 4,346,321 |
| Open | 13.88 |
| Previous Close | 13.83 |
| Day's Range | 13.68 - 14.36 |
| 52-Week Range | 6.84 - 15.63 |
| Beta | 1.21 |
| RSI | 58.91 |
| Earnings Date | Mar 16, 2026 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]
Financial Performance
In 2025, HKG:0867's revenue was 8.21 billion, an increase of 9.95% compared to the previous year's 7.47 billion. Earnings were 1.49 billion, a decrease of -8.08%.
Financial numbers in CNY Financial StatementsNews
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an i...
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VI...